‘Entire cell therapy sector’ realizes importance of supply chain management

By Maggie Lynch contact

- Last updated on GMT

(Image: Getty/CI Photos)
(Image: Getty/CI Photos)

Related tags: Supply chain management, Supply chain, Clinical development, Personalized medicine, Cell therapy, Gene therapy

TrakCel will build a supply chain tracking platform to manage the clinical development of WindMIL’s personalized cellular therapies.

The supply chain platform will manage WindMIL’s supply chain as it expands its involvement in clinical trials for its cell therapies. The platform will be live in over 100 sites globally and, according to the two companies. The site will aim to ‘harmonize’ all partner internal systems, as WindMIL expands its clinical trial footprint after a $32.5m (€28.45m) Series B fundraising.

WindMIL’s cell therapy pipeline, based on its expertise in bone marrow immunology, includes the only replicable and scalable process to create a cell therapy product from bone marrow-derived T cells.

This partnership is aimed increasing transparency of collection, transportation, and manufacturing through the supply chain during clinical trials. 

Brian Halak, president and CEO of WindMIL said in a statement that this platform is important for its expansion into clinical trials as, “developing novel cellular therapies is also about logistics. It is important for us to ensure the supply chain works for each of the individuals involved in the patient’s care and for the oncology patients themselves.”

TrakCel’s CEO, Ravi Nalliah, added in a statement that the “entire cell therapy sector”​ is realizing the importance of supply chain tracking from an early stage. Due to this realization, the company is working with multiple companies in various stages of clinical development for supply chain management.

“The opportunity cost of the resources used for managing supply chains is even more important for companies at the earlier clinical stage. This means it is essential for TrakCel to continue to develop our cell therapy supply chain solutions as the cell therapy market continues to evolve,”​ Nalliah said. 

Related news

Related products

show more

rAAV Production in BioBLU® Single-Use Vessels

rAAV Production in BioBLU® Single-Use Vessels

Eppendorf for Bioprocess – Solutions that grow with you | 25-Jun-2019 | Application Note

Rising interest in gene therapy-based applications leads to increasing demands in scalable production systems for viral vectors. Find out how Cevec Pharmaceuticals...

Small-Scale Cell Culture Perfusion Process

Small-Scale Cell Culture Perfusion Process

Eppendorf for Bioprocess – Solutions that grow with you | 29-Mar-2019 | Application Note

Perfusion cell culture processes promise advantages for industrial bioprocessing, like saving space, increasing volumetric productivity, achieving more...

Cultivation of 3D Cell Aggregates in Perfusion

Cultivation of 3D Cell Aggregates in Perfusion

Eppendorf for Bioprocess – Solutions that grow with you | 17-Sep-2018 | Application Note

3D cell aggregates are of great interest for applications like disease modeling and manufacturing of stem cell-based products. Read more about the cultivation...

Nifty Biosimilar

Nifty Biosimilar

UGA Biopharma | 13-Mar-2018 | Research Study

Aflibercept (Zaltrap®) is a recombinant fusion protein with complex post-translational modifications. Therefore deep understanding of biosimilar development...

Related suppliers

Follow us

Products

View more

Webinars